Trial Profile

A Phase II Clinical Study of Anti-CD19 CAR-T Therapy (pCAR-19B) in the Treatment of CD19-positive Relapsed/Refractory B-ALL

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 10 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

07 Nov 2025 According to Chongqing Precision Biotech Co., Ltd media release, company announced that Puzolcabtagene Autoleucel Injection (pCAR-19B) has received marketing approval from the National Medical Products Administration (NMPA).
10 Dec 2024 Results (As of April 18th, 2024, n=89) assessing efficacy and safety outcomes of pCAR-19B in a pivotal clinical trial involving Chinese pediatric and young adult patients with R/R B-cell ALL, presented at the 66th American Society of Hematology Annual Meeting and Exposition.
31 Jul 2024 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com